In contrast to these findings, other studies have found lower plasma ApoA-II levels in patients with AD compared to controls in a Japanese cohort [33] and, in mild cognitive impairment (MCI) patients, lower ApoA-II increased the risk of cognitive decline [34]. This evidence concerns the gene APOA2 and Mental deterioration.